MCI — Medcaw Investments Share Price
- £0.69m
- £0.52m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | -449.2% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Medcaw Investments plc is a United Kingdom-based shell company. The Company’s primary objective is to identify and acquire prospective lithium mining projects across Africa. It has entered into a binding conditional agreement to acquire Abyssinian Metals Limited (AML), a company developing the Kenticha lithium project located in Oromia State, Southern Ethiopia. The Kenticha project is a highly evolved, rare element, lithium Cesium tantalum (LCT) pegmatite project, comparable to other major rare-element pegmatites such as Greenbushes, Tanco, Wodgina, Volta Grande and Altai No.3. Kenticha is a late-stage development asset which AML intends to develop with the production of spodumene concentrate planned in stages, with near-term production through a dense medium separation (DMS) modular plant.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 11th, 2020
- Public Since
- December 21st, 2022
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
London Stock Exchange
- Shares in Issue
- 17,132,095

- Address
- Eccleston Yards, 25 Eccleston Place, LONDON, SW1W 9NF
- Web
- https://medcaw-invest.com/investors/
- Phone
- +44 2039188797
- Auditors
- Crowe U.K. LLP
Similar to MCI
Adalan Ventures
London Stock Exchange
Ajax Resources
London Stock Exchange
Amala Foods
London Stock Exchange
Ashington Innovation
London Stock Exchange
Bay Capital
London Stock Exchange
FAQ
As of Today at 21:58 UTC, shares in Medcaw Investments are trading at 4.00p. This share price information is delayed by 15 minutes.
Shares in Medcaw Investments last closed at 4.00p and the price had moved by over the past 365 days. In terms of relative price strength the Medcaw Investments share price has underperformed the FTSE All Share Index by -2.74% over the past year.
There is no consensus recommendation for this security.
Find out moreMedcaw Investments does not currently pay a dividend.
Medcaw Investments does not currently pay a dividend.
Medcaw Investments does not currently pay a dividend.
To buy shares in Medcaw Investments you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 4.00p, shares in Medcaw Investments had a market capitalisation of £0.69m.
Here are the trading details for Medcaw Investments:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: MCI
Based on an overall assessment of its quality, value and momentum Medcaw Investments is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medcaw Investments. Over the past six months, its share price has underperformed the FTSE All Share Index by -0.48%.
As of the last closing price of 4.00p, shares in Medcaw Investments were trading -33.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medcaw Investments PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 4.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Medcaw Investments' directors